Skip to content
  • Reports
  • Podcast Subscribe
  • Log In

Now covering the global biotech industry!
Read More
Topics
  • CRISPR
  • CAR-T
  • Covid-19
  • Microbiome
  • mRNA technology
  • Gene therapy
  • CRISPR
  • CAR-T
  • Covid-19
  • Microbiome
  • mRNA technology
  • Gene therapy
  • Log In
Now covering the global biotech industry!
Read More

Home » What’s new » GeNeuro

GeNeuro

ADVERTISEMENT
News and Trends

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…

By Jonathan Smith
September 17, 2019 - 4 minutes
News and Trends

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome…

By Jonathan Smith
March 12, 2019 - 3 minutes
More News!

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in…

By Clara Rodríguez Fernández
March 26, 2018 - 2 minutes
News and Trends

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro's antibody for the treatment of a…

By Alex Dale
February 26, 2018 - 2 minutes
More News!

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in…

By Evelyn Warner
November 1, 2017 - 2 minutes
Best in Biotech

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…

By Denise Neves Gameiro
May 30, 2017 - 7 minutes
In Depth

How Biotech is Mastering Multiple Sclerosis: A Review

With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis.…

By Diana Kwon
April 25, 2017 - 7 minutes
News and Trends

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company's CFO, who…

By Clara Rodríguez Fernández
September 30, 2016 - 1 minute
News and Trends

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO…

By Dani Bancroft
April 16, 2016 - 2 minutes
News and Trends

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought…

By Julie Lellouche
December 15, 2014 - 2 minutes
footer logo

Labiotech.eu is the leading digital media covering the global biotech industry.

Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you’ll enjoy reading our stories!

  • About us
  • Inside Labiotech
  • Join Us
  • Advertise
  • Contact
  • Editorial Calendar
  • Site Map
  • Linkedin
  • Twitter
  • Youtube
  • RSS Feed
Made with in Berlin. Labiotech UG, All Rights Reserved -
  • Imprint
  • Privacy Policy

Browse Topics

Search for a topic, country or company name by using the search box

    Popular topics:


    CRISPR mRNA technology CAR-T HIV Cell therapy Diabetes Microbiome Gene therapy Synthetic biology
    Labiotech.eu
    • Log In

    Topics

    • Gene Therapy
    • CRISPR
    • CAR-T
    • Covid-19
    • Microbiome
    • Diabetes
    • Cancer

    Sections

    • News and Trends
    • In Depth
    • Best in Biotech
    • Opinion
    • Interview
    • Infographics
    Show All Topics

    For Members

    • Expert Advice
    • Reports
    • Startup Scout

    More

    • About us
    • Inside Labiotech
    • Join Us
    • Advertise
    • Contact
    • Podcast
    • Biotech Events
    • Awareness Days